OMCAZIO - (EQ 11.5MG BASE, EQ 23MG BASE, EQ 34.5MG BASE; CAPSULE)

Generic Name	CABOZANTINIB LAURYLSULFATE	**Innovator**	HANDA ONCOL
Dosage	EQ 11.5MG BASE, EQ 23MG BASE, EQ 34.5MG BASE; CAPSULE	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	OMCAZIO is a kinase inhibitor indicated for the treatment of • patients with advanced renal cell carcinoma (RCC). • patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab. • patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. • adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET).		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.